Indonesia's Food and Drug Monitoring Agency (BPOM) has approved the expanded use of the measles vaccine for at-risk adult groups, a decision made on April 7, 2026, to combat ongoing measles outbreaks. This public health emergency has seen 58 outbreaks across 39 districts and cities in 14 provinces as of the 11th week of 2026, though cases have significantly declined from a mid-March peak. BPOM head Taruna Ikrar stated the approval followed a rigorous scientific evaluation, including consultation with the WHO and analysis of clinical trial data, ensuring the safety, quality, and efficacy of Bio Farma's domestically produced vaccine for adults. This move aims to optimize vaccine use for adult immunization, prioritizing high-risk individuals like healthcare workers and international travelers, with sufficient national stock of approximately 9.8 million doses.